Clinuvel Pharmaceuticals Limited (ASX:CUV) is a leading and innovative Australian company focused on the development of afamelanotide, its proprietary first-in-class photoprotective drug. Clinuvel has identified five groups of patients with a clinical need for photoprotection. Currently, Clinuvel is in its final stages to complete testing of afamelanotide in Phase II and III trials in Australia and Europe. 
Results released today from a Phase III trial of the drug SCENESSE (R), conducted by Melbourne-based Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY), have shown that the drug has the ability to reduce and prevent painful phototoxic reactions experienced by patients with erythropoietic protoporphyria (EPP).
Melbourne's Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY) today signed with a commercial US partner to manufacture its world's first photoprotective drug, SCENESSE (R), under an exclusive arrangement. Following eight years of development, Clinuvel has selected Surmodics, Inc. (NASDAQ:SRDX), a leading Minnesota-based provider of proprietary drug delivery technologies to the healthcare industry, as its first manufacturing partner.
